Acute Myeloid Leukaemia Highlights from EHA 2026: Targeted Treatments, Combination Regimens, and CAR-T Therapy

This podcast was funded by Servier.

The opinions expressed in this podcast belong solely to Sue Saville, Remco J. Molenaar, Joshua F. Zeidner, Ana Alfonso Piérola, and Alessandro Isidori.

In this podcast, moderator Sue Saville is joined by Remco J. Molenaar, Joshua F. Zeidner, Ana Alfonso Piérola, and Alessandro Isidori to discuss acute myeloid leukaemia (AML) research presented at EHA 2026. The panel reviews the role of molecular profiling in treatment selection, with particular focus on IDH1-mutated AML and findings from ALIDHE, AGILE, and studies of ivosidenib-based doublet and triplet regimens. The experts also consider venetoclax treatment duration, emerging evidence for FLT3 and menin inhibitors, the potential and challenges of CAR-T therapy in AML, and future directions for personalised treatment.

1. Independent Health Communications Specialist, UK
2. Amsterdam UMC, the Netherlands
3. UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, USA
4. Clínica Universidad de Navarra and Cancer Center Clínica Universidad de Navarra, Spain
5. Hematology and Stem Cell Transplant Center, AST Pesaro e Urbino, Italy